Scarica l'app Stockscreener
1.43
6.72%
0.09
Precedente Chiudi:
$1.34
Aprire:
$1.35
Volume 24 ore:
294.08K
Relative Volume:
1.58
Capitalizzazione di mercato:
$22.75M
Reddito:
$345.00K
Utile/perdita netta:
$-11.25M
Rapporto P/E:
-1.9814
EPS:
-0.7217
Flusso di cassa netto:
$-16.70M
1 W Prestazione:
-7.74%
1M Prestazione:
+0.00%
6M Prestazione:
+39.51%
1 anno Prestazione:
+64.08%
Intervallo 1D:
$1.28
$1.4799
Intervallo di 1 settimana:
$1.28
$1.5799
Portata 52W:
$0.7687
$2.35
Allarity Therapeutics Inc Stock (ALLR) Company Profile
Nome
Allarity Therapeutics Inc
Settore
Industria
Telefono
401-426-4664
Indirizzo
24 SCHOOL ST., 2ND FLOOR, BOSTON
Compare ALLR vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
1.43 | 22.75M | 345.00K | -11.25M | -16.70M | -0.7217 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Allarity Therapeutics Inc Stock (ALLR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-28 | Iniziato | Ascendiant Capital Markets | Buy |
Allarity Therapeutics Inc Borsa (ALLR) Ultime notizie
Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Allarity to present trial poster at cancer congress - Investing.com
Allarity takes Phase 2 ovarian cancer trial to ESMO Congress - Stock Titan
Allarity Therapeutics Inc (ALLR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Allarity Therapeutics Inc (ALLR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Allarity Therapeutics Inc (ALLR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Allarity Therapeutics Inc (ALLR) Institutional Confidence - TradingKey
Allarity Therapeutics Inc (ALLR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Allarity Therapeutics Inc (ALLR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Allarity Therapeutics Inc (ALLR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Allarity Therapeutics Inc (ALLR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
ALLR Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost DisciplineNet Profit Margin - newsline.com
ALLR Maintained by Ascendiant Capital -- Price Target Raised to $10.25 - GuruFocus
Allarity Therapeutics (ALLR) Slides 5.3% as Stock Tests Critical Support LevelGap Fill Strategy - newsline.com
Are medical stocks lagging Allarity Therapeutics, Inc. (ALLR) this year? - MSN
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year? - Yahoo Finance
Amended and Restated Management Services Agreement Between Allarity Therapeutics, Inc. and Ljungaskog Consulting AB Effective June 1, 2026 - Minichart
Allarity Therapeutics Updates CEO Management and Compensation Agreement - TipRanks
Allarity (NASDAQ: ALLR) updates CEO pay and severance terms - Stock Titan
Number of shareholders of Allarity Therapeutics, Inc. – NASDAQ:ALLR - TradingView
ALLR Q1 2026 Earnings: Narrower Loss Surprises as Pre-Revenue Biotech Advances PipelineGuidance Downgrade Alert - The Legal Advocate
Allarity Therapeutics (ALLR) Faces Selling Pressure, Holds Above Key SupportVolatility Smile - thelegaladvocate.com
Allarity Therapeutics (ALLR) Slides 4.8% in Session; Key Support Levels in FocusGEX Level - newsline.com
Allarity Therapeutics (ALLR) Surges 6.6% as Volume Picks Up, Testing Key ResistanceOption Breadth - The Legal Advocate
Allarity (ALLR) Posts Q1 2026 Earnings Beat — Here's What Drove ItPre-Announcement Alert - The Legal Advocate
Allarity (ALLR) Delivers Q1 2026 Beat — EPS $-0.17 vs $-0.22 ExpectedEarnings Season Preview - The Legal Advocate
Are Medical Stocks Lagging Bioventus (BVS) This Year? - Yahoo Finance
Allarity Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Allarity Therapeutics Advances Stenoparib Development for Cancer Treatments and Strengthens Financial Position - Quiver Quantitative
Allarity Therapeutics Q1 net loss per share narrows - TradingView
U.S. VA backs trial of Allarity cancer drug for relapsed lung patients - Stock Titan
Allarity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Allarity Therapeutics (ALLR) posts Q1 2026 loss but lifts cash with $20M notes - Stock Titan
Allarity Therapeutics (ALLR) CEO receives 200,000-share RSU equity grant - Stock Titan
Why Allarity (ALLR) Just Dropped -1.30% — What to Watch 2026-05-14Trade Entry - newser.com
Director Jesper Hoeiland receives 25,000-share grant at Allarity (ALLR) - Stock Titan
Director Jesper Hoeiland joins Allarity Therapeutics (ALLR) with initial Form 3 filing - Stock Titan
Allarity Therapeutics Advances Stenoparib, a Dual PARP and WNT Inhibitor with DRP® Companion Diagnostic, in Phase 2 Cancer Trials - Minichart
Allarity Highlights Stenoparib Progress in New Investor Presentation - TipRanks
Allarity details stenoparib data, CEO to speak in Europe | ALLR 8-K Filing - Stock Titan
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm - The Manila Times
Allarity Therapeutics CEO Thomas Jensen to Speak at Precision Medicine Forum Europe 2026 - Quiver Quantitative
Allarity CEO to outline cancer drug trial work at Stockholm forum - Stock Titan
Director at Allarity Therapeutics (ALLR) receives 45,000 RSUs in grant - Stock Titan
PARP Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics - TMX Newsfile
Allarity Therapeutics Advances Stenoparib Toward Phase 3 and FDA Approval in Ovarian Cancer with Manufacturing Milestone - Minichart
Stenoparib Phase 3 manufacturing on track as Allarity (NASDAQ: ALLR) preps trials - Stock Titan
Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign - Investing News Network
Allarity advances stenoparib manufacturing for pivotal trial By Investing.com - Investing.com South Africa
Allarity Therapeutics Inc Azioni (ALLR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):